These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 26773675

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.
    Koo DL, Joo EY, Kim D, Hong SB.
    Epilepsy Res; 2013 Mar; 104(1-2):134-9. PubMed ID: 23032070
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients.
    El-Haggar SM, Mostafa TM, Allah HMS, Akef GH.
    Arq Neuropsiquiatr; 2018 Jul; 76(7):452-458. PubMed ID: 30066796
    [Abstract] [Full Text] [Related]

  • 5. Monotherapy with Levetiracetam Versus Older AEDs: A Randomized Comparative Trial of Effects on Bone Health.
    Hakami T, O'Brien TJ, Petty SJ, Sakellarides M, Christie J, Kantor S, Todaro M, Gorelik A, Seibel MJ, Yerra R, Wark JD.
    Calcif Tissue Int; 2016 Jun; 98(6):556-65. PubMed ID: 26842957
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine.
    Serin HM, Koç ZP, Temelli B, Esen İ.
    Epilepsy Behav; 2015 Oct; 51():221-4. PubMed ID: 26298867
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Experience with levetiracetam in the treatment of childhood refractory epilepsy].
    Doumbia-Ouattara M, Bourel-Ponchel E, Le Moing AG, Querne L, Delignières A, de Broca A, Berquin P.
    Arch Pediatr; 2012 Jan; 19(1):3-8. PubMed ID: 22169571
    [Abstract] [Full Text] [Related]

  • 10. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy.
    Phabphal K, Geater A, Limapichat K, Sathirapanya P, Setthawatcharawanich S, Leelawattana R.
    Epilepsia; 2013 Jun; 54(6):e94-8. PubMed ID: 23586623
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy.
    Beerhorst K, Tan IY, De Krom M, Verschuure P, Aldenkamp AP.
    Acta Neurol Scand; 2013 Oct; 128(4):273-80. PubMed ID: 23461582
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of treatment with inhaled corticosteroids on bone mineral density of patients with asthma: related with age.
    Monadi M, Javadian Y, Cheraghi M, Heidari B, Amiri M.
    Osteoporos Int; 2015 Jul; 26(7):2013-8. PubMed ID: 25860975
    [Abstract] [Full Text] [Related]

  • 15. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
    Trinka E, Marson AG, Van Paesschen W, Kälviäinen R, Marovac J, Duncan B, Buyle S, Hallström Y, Hon P, Muscas GC, Newton M, Meencke HJ, Smith PE, Pohlmann-Eden B, KOMET Study Group.
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
    [Abstract] [Full Text] [Related]

  • 16. Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy.
    Shukla G, Gupta A, Agarwal P, Poornima S.
    Epilepsy Behav; 2016 Nov; 64(Pt A):216-218. PubMed ID: 27756024
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy].
    Bauer J, Pfeiffer C, Burr W.
    Nervenarzt; 2010 Apr; 81(4):391-5. PubMed ID: 20111854
    [Abstract] [Full Text] [Related]

  • 19. Retention rate of levetiracetam in children with intractable epilepsy at 1 year.
    Peake D, Mordekar S, Gosalakkal J, Mukhtyar B, Buch S, Crane J, Wheway R, Rittey C, Donnelly J, Whitehouse WP, Philip S.
    Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.